|
Aug 18
|
Novo Nordisk's Wegovy Snags Conditional FDA Nod For Fatty Liver Disease
|
|
Aug 18
|
Novo Nordisk shares up as Wegovy gets US nod for liver treatment
|
|
Aug 18
|
Analysis-Wall Street sees new obesity pills as priced near Wegovy and Zepbound
|
|
Aug 18
|
Echosens and Novo Nordisk Advance Partnership to Increase Awareness and Early Diagnosis of MASH
|
|
Aug 18
|
Novo Nordisk's Wegovy Gets FDA Approval for Noncirrhotic MASH With Fibrosis
|
|
Aug 18
|
Trending tickers: Novo Nordisk, Palo Alto Networks, Walmart, Soho House and Nio
|
|
Aug 18
|
Shares in Novo Nordisk rise after Wegovy gets US nod for liver disease treatment
|
|
Aug 17
|
1 Stock Down 40% This Year to Buy and Hold
|
|
Aug 17
|
1 Beaten-Down Stock That Could Soar by the End of the Year
|
|
Aug 17
|
This Healthcare Stock's Bad News Could Create a $10 Billion Opportunity for Competitors
|
|
Aug 17
|
Novo Nordisk A/S (NVO) Delivers 18% Sales Growth in H1 2025
|
|
Aug 16
|
BNP Paribas Exane Upgrades Novo Nordisk (NVO) to Neutral from Underperform
|
|
Aug 15
|
Wegovy® approved by FDA for the treatment of adults with noncirrhotic MASH with moderate to advanced liver fibrosis
|
|
Aug 15
|
Novo Nordisk A/S: Wegovy® approved in the US for the treatment of MASH
|
|
Aug 15
|
Why Novo Nordisk Flew Almost 3% Higher on Friday
|
|
Aug 15
|
Novo Nordisk's Lead Fades, Eli Lilly Holds Course For Outsized Gains, Says Analyst
|
|
Aug 15
|
Novo Nordisk Stock Could Benefit From Eli Lilly’s Weight-Loss Price Hikes
|
|
Aug 15
|
European Equities Traded in the US as American Depositary Receipts Edge Lower in Friday Trading
|
|
Aug 15
|
Will New CEO's Leadership Propel Novo Nordisk's Next Growth Wave?
|
|
Aug 15
|
Big Pharma Has a New Vision for Selling Drugs. It’s Going to the Mattresses.
|